MAINTAIN - MAintain Functions and INTrinsec capacities with Aging :
Preventive and personalized INterventional Research

Equipe constitutive du CERPOP, UMR 1295, unité mixte INSERM - Université Toulouse III Paul Sabatier
Bruno VELLAS •  chercheur

  1. Angioni D, Lu WH, Sourdet S, Macaron T, Takeda C, Guyonnet S, Mangin JF, Rolland Y, de Souto Barreto P, Vellas B. Biomarkers of Age-Related Frailty and Frailty Related to Diseases: An Exploratory, Cross-Sectional Analysis from the MAPT Study. J Nutr Health Aging. 2022;26(6):545-551. doi: 10.1007/s12603-022-1793-9.
  2. Bateman RJ, Cummings J, Schobel S, Salloway S, Vellas B, Boada M, Black SE, Blennow K, Fontoura P, Klein G, Assunção SS, Smith J, Doody RS. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease. Alzheimers Res Ther. 2022 Nov 29;14(1):178. doi: 10.1186/s13195-022-01110-8.
  3. Bencivenga L, Strumia M, Rolland Y, Martinez L, Cestac P, Guyonnet S, Andrieu S, Parini A, Lucas A, Vellas B, De Souto Barreto P, Rouch L; MAPT/D. S. A. group. Biomarkers of mitochondrial dysfunction and inflammaging in older adults and blood pressure variability. Geroscience. 2022 Dec 1. doi: 10.1007/s11357-022-00697-y. Epub ahead of print.
  4. Bencivenga L, De Souto Barreto P, Rolland Y, Hanon O, Vidal JS, Cestac P, Vellas B, Rouch L. Blood pressure variability: A potential marker of aging. Ageing Res Rev. 2022 Sep;80:101677. doi: 10.1016/j.arr.2022.101677.
  5. Belleville S, Cloutier S, Mellah S, Willis S, Vellas B, Andrieu S, Coley N, Ngandu T; MAPT/DSA group. Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia. Alzheimers Dement. 2022 Nov;18(11):2140-2150. doi: 10.1002/alz.12544.
  6. Belleville S, Cloutier S, Mellah S, Vellas B, Andrieu S, Coley N, Ngandu T. Response to "Upping the dose of dementia risk reduction". Alzheimers Dement. 2022 Sep;18(9):1700-1701. doi: 10.1002/alz.12693.
  7. Bernabei R, Landi F, Calvani R, Cesari M, Del Signore S, Anker SD, Bejuit R, Bordes P, Cherubini A, Cruz-Jentoft AJ, Di Bari M, Friede T, Gorostiaga Ayestarán C, Goyeau H, Jónsson PV, Kashiwa M, Lattanzio F, Maggio M, Mariotti L, Miller RR, Rodriguez-Mañas L, Roller-Wirnsberger R, Rýznarová I, Scholpp J, Schols AMWJ, Sieber CC, Sinclair AJ, Skalska A, Strandberg T, Tchalla A, Topinková E, Tosato M, Vellas B, von Haehling S, Pahor M, Roubenoff R, Marzetti E; SPRINTT consortium. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). BMJ. 2022 May 11;377:e068788. doi: 10.1136/bmj-2021-068788.
  8. Bischoff-Ferrari HA, Willett WC, Manson JE, Dawson-Hughes B, Manz MG, Theiler R, Braendle K, Vellas B, Rizzoli R, Kressig RW, Staehelin HB, Da Silva JAP, Armbrecht G, Egli A, Kanis JA, Orav EJ, Gaengler S. Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program May Reduce Cancer Risk Among Active Adults Aged 70 and Older: A Randomized Clinical Trial. Front Aging. 2022 Apr 25;3:852643. doi: 10.3389/fragi.2022.852643.
  9. Bischoff-Ferrari HA, Freystätter G, Vellas B, Dawson-Hughes B, Kressig RW, Kanis JA, Willett WC, Manson JE, Rizzoli R, Theiler R, Hofbauer LC, Armbrecht G, da Silva JAP, Blauth M, de Godoi Rezende Costa Molino C, Lang W, Siebert U, Egli A, Orav EJ, Wieczorek M; DO-HEALTH Research Group. Effects of vitamin D, omega-3 fatty acids and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. Am J Clin Nutr. May 1;115(5):1311-1321. doi: 10.1093/ajcn/nqac022.
  10. Brody M, Agronin M, Herskowitz BJ, Bookheimer SY, Small GW, Hitchinson B, Ramdas K, Wishard T, McInerney KF, Vellas B, Sierra F, Jiang Z, Mcclain-Moss L, Perez C, Fuquay A, Rodriguez S, Hare JM, Oliva AA Jr, Baumel B. Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease. Alzheimers Dement. 2022 Mar 31. doi: 10.1002/alz.12651. Epub ahead of print.
  11. Calcaterra L, Proietti M, Saporiti E, Nunziata V, Rolland Y, Vellas B, Cesari M. Predictors of drug prescription in nursing home residents: results from the INCUR study. Intern Emerg Med. 2022 Jan;17(1):165-171. doi: 10.1007/s11739-021-02841-6.
  12. Cesari M, Bernabei R, Vellas B, Fielding RA, Rooks D, Azzolino D, Mariani J, Oliva AA, Bhasin S, Rolland Y. Challenges in the Development of Drugs for Sarcopenia and Frailty - Report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force. J Frailty Aging. 2022;11(2):135-142. doi: 10.14283/jfa.2022.30.
  13. Coley N, Giulioli C, Aisen PS, Vellas B, Andrieu S. Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review. Ageing Res Rev. 2022 Dec;82:101777. doi: 10.1016/j.arr.2022.101777.
  14. Da Silva JP, Wargny M, Raffin J, Croyal M, Duparc T, Combes G, Genoux A, Perret B, Vellas B, Guyonnet S, Thalamas C, Langin D, Moro C, Viguerie N, Rolland Y, Barreto PS, Cariou B, Martinez LO; MAPT/DSA Group. Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: a prospective cohort study. Diabetes Metab. 2022 Sep 26:101391. doi: 10.1016/j.diabet.2022.101391. Epub ahead of print.
  15. de Godoi Rezende Costa Molino C, Chocano-Bedoya PO, Sadlon A, Theiler R, Orav JE, Vellas B, Rizzoli R, Kressig RW, Kanis JA, Guyonnet S, Lang W, Egli A, Bischoff-Ferrari HA; DO-HEALTH Research Group. Prevalence of polypharmacy in community-dwelling older adults from seven centres in five European countries: a cross-sectional study of DO-HEALTH. BMJ Open. 2022 Apr 29;12(4):e051881. doi: 10.1136/bmjopen-2021-051881.
  16. de Souto Barreto P, Fabre D, Vellas B, Blain H, Molinier L, Rolland Y. Reduction prevalence of fragility fracture hospitalisation during the COVID-19 lockdown. Arch Osteoporos. 2022 Apr 18;17(1):68. doi: 10.1007/s11657-022-01099-5.
  17. de Souto Barreto P, Cesari M, Morley JE, Roberts S, Landi F, Cederholm T, Rolland Y, Vellas B, Fielding R. Appetite Loss and Anorexia of Aging in Clinical Care: An ICFSR Task Force Report. J Frailty Aging. 2022;11(2):129-134. doi: 10.14283/jfa.2022.14.
  18. Fougère B, Goisser S, Cantet C, Soriano G, Guyonnet S, De Souto Barreto P, Cesari M, Andrieu S, Vellas B; MAPT Study Group. Retraction Note to: Omega-3 fatty acid levels in red blood cell membranes and physical decline over 3 years: longitudinal data from the MAPT study. Geroscience. Apr;44(2):1173. doi: 10.1007/s11357-021-00505-z.
  19. Gonthier R, Adolphe M, Michel JP, Bringer J, Dubois B, Lecomte D, Milliez J, Vellas B; commission XIII (autonomie-dépendance-vieillissement) de l’Académie nationale de médecine. Rapport 22-02. Après la crise COVID, quelles solutions pour l’EHPAD de demain ? [After the COVID crisis, what solutions for the future nursing home?]. Bull Acad Natl Med. 2022 Apr;206(4):457-465 . doi: 10.1016/j.banm.2022.02.010.
  20. Gonzalez-Bautista E, Barreto PS, Salinas-Rodriguez A, Manrique Espinoza B, Sourdet S, Rolland Y, Rodriguez-Mañas L, Andrieu S, Vellas B; MAPT/DSA group. Development and validation of a cut-off for the chair stand test as a screening for mobility impairment in the context of the integrated care for older people (ICOPE) program. J Gerontol A Biol Sci Med Sci. 2022 Feb 28:glac055. doi: 10.1093/gerona/glac055. Epub ahead of print.
  21. Giudici KV, Guyonnet S, Cantet C, de Souto Barreto P, Weiner MW, Tosun D, Boschat C, Hudry J, Andrieu S, Vellas B, Schmitt JAJ; Nolan/DSA group. A 1-year randomized controlled trial of a nutritional blend to improve nutritional biomarkers and prevent cognitive decline among community-dwelling older adults: The Nolan Study. Alzheimers Dement (N Y). 2022 Sep 28;8(1):e12314. doi: 10.1002/trc2.12314.
  22. Giudici KV, Guyonnet S, Morley JE, Nguyen AD, Aggarwal G, Parini A, Li Y, Bateman RJ, Vellas B, de Souto Barreto P; MAPT/DSA Group. Interactions Between Weight Loss and Plasma Neurodegenerative Markers for Determining Cognitive Decline Among Community-Dwelling Older Adults. J Gerontol A Biol Sci Med Sci. 2022 Jun 1;77(6):1159-1168. doi: 10.1093/gerona/glac015.
  23. Gonçalves RSDSA, Maciel ÁCC, Rolland Y, Vellas B, de Souto Barreto P. Frailty biomarkers under the perspective of geroscience: A narrative review. Ageing Res Rev. 2022 Nov;81:101737. doi: 10.1016/j.arr.2022.101737.
  24. Gonzalez-Bautista E, de Souto Barreto P, Salinas-Rodriguez A, Manrique-Espinoza B, Rolland Y, Andrieu S, Vellas B; MAPT/DSA group. Clinically meaningful change for the chair stand test: monitoring mobility in integrated care for older people. J Cachexia Sarcopenia Muscle. 2022 Oct;13(5):2331-2339. doi: 10.1002/jcsm.13042.
  25. He L, Barreto PS, Sánchez Sánchez JL, Rolland Y, Guyonnet S, Parini A, Lucas A, Vellas B; MAPT/DSA Group. Prospective associations of plasma growth differentiation factor 15 with physical performance and cognitive functions in older adults. J Gerontol A Biol Sci Med Sci. 2022 Jan 17:glac020. doi: 10.1093/gerona/glac020. Epub ahead of print.
  26. Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Baret-Rose C, Tréluyer JM, Abdoul H, Gelé P, Delmaire C, Blanc F, Mangin JF, Buée L, Touchon J, Hugon J, Vellas B, Galbrun E, Benetos A, Berrut G, Paillaud E, Wallon D, Castelnovo G, Volpe-Gillot L, Paccalin M, Robert P, Godefroy O, Camus V, Belmin J, Vandel P, Novella JL, Duron E, Rigaud AS, Schraen-Maschke S, Gabelle A; BALTAZAR study group. Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. Alzheimers Dement. 2022 Feb 20. doi: 10.1002/alz.12613. Epub ahead of print.
  27. Kemoun P, Ader I, Planat-Benard V, Dray C, Fazilleau N, Monsarrat P, Cousin B, Paupert J, Ousset M, Lorsignol A, Raymond-Letron I, Vellas B, Valet P, Kirkwood T, Beard J, Pénicaud L, Casteilla L. A gerophysiology perspective on healthy ageing. Ageing Res Rev. 2022 Jan;73:101537. doi: 10.1016/j.arr.2021.101537.
  28. Lu WH, Giudici KV, Morley JE, Guyonnet S, Parini A, Aggarwal G, Nguyen AD, Li Y, Bateman RJ, Vellas B, de Souto Barreto P; MAPT/DSA Group. Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults. Geroscience. 2022 Jun;44(3):1489-1503. doi: 10.1007/s11357-022-00554-y.
  29. Lu WH, Vellas B, de Souto Barreto P. Reply to: Comment on: The associations of plasma neurofilament light chain and progranulin with frailty in older adults. J Am Geriatr Soc. 2022 Jul;70(7):2169-2170. doi: 10.1111/jgs.17782.
  30. Molet-Benhamou L, Giudici KV, de Souto Barreto P, Cantet C, Rolland Y; MAPT/DSA group (Vellas B collaborator). Association between urate-lowering therapies and cognitive decline in community-dwelling older adults. Sci Rep. 2022 Sep 12;12(1):15299. doi: 10.1038/s41598-022-17808-6.
  31. Mortamais M, Gutierrez LA, Balem M, Bars EL, de Champfleur NM, Bouyahia A, Chupin M, Perus L, Fisher C, Vellas B, Andrieu S, Mangin JF, Berr C, Gabelle A; MAPT/DSA study group. Sulcal morphology as cognitive decline predictor in older adults with memory complaints. Neurobiol Aging. 2022 May;113:84-94. doi: 10.1016/j.neurobiolaging.2022.02.003.
  32. Mura T, Coley N, Amieva H, Berr C, Gabelle A, Ousset PJ, Vellas B, Andrieu S; GuidAge/DSA study group*. Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials. Alzheimers Dement. 2022 Apr;18(4):676-687. doi: 10.1002/alz.12431.
  33. Nguyen AD, Malmstrom TK, Aggarwal G, Miller DK, Vellas B, Morley JE. Serum neurofilament light levels are predictive of all-cause mortality in late middle-aged individuals. EBioMedicine. 2022 Aug;82:104146. doi: 10.1016/j.ebiom.2022.104146.
  34. Oviedo-Briones M, Rodríguez-Laso Á, Carnicero JA, Gryglewska B, Sinclair AJ, Landi F, Vellas B, Rodríguez Artalejo F, Checa-López M, Rodriguez-Mañas L. The ability of eight frailty instruments to identify adverse outcomes across different settings: the FRAILTOOLS project. J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1487-1501 . doi: 10.1002/jcsm.12990.
  35. Pagès A, Costa N, González-Bautista E, Mounié M, Juillard-Condat B, Molinier L, Cestac P, Rolland Y, Vellas B, De Souto Barreto P; MAPT/DSA Group. Screening for deficits on intrinsic capacity domains and associated healthcare costs. Arch Gerontol Geriatr. 2022 May-Jun;100:104654. doi: 10.1016/j.archger.2022.104654.
  36. Pagès A, Costa N, Mounié M, Cestac P, De Souto Barreto P, Rolland Y, Vellas B, Molinier L, Juillard-Condat B; MAPT/DSA Group. Healthcare Costs Associated with Potentially Inappropriate Medication Prescribing Detected by Computer Algorithm Among Older Patients. Drugs Aging. 2022 May;39(5):367-375. doi: 10.1007/s40266-022-00938-x.
  37. Pires Da Silva J, Wargny M, Raffin J, Croyal M, Duparc T, Combes G, Genoux A, Perret B, Vellas B, Guyonnet S, Thalamas C, Langin D, Moro C, Viguerie N, Rolland Y, Barreto PS, Cariou B, Martinez LO; MAPT/DSA Group. Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study. Diabetes Metab. 2022 Sep 26;49(1):101391. doi: 10.1016/j.diabet.2022.101391. Epub ahead of print.
  38. Raffin J, Angioni D, Giudici KV, Valet P, Aggarwal G, Nguyen AD, Morley JE, Guyonnet S, Rolland Y, Vellas B, Barreto PS; MAPT/DSA Group. Physical activity, body mass index, and blood progranulin in older adults: cross-sectional associations in the MAPT study. J Gerontol A Biol Sci Med Sci. 2022 Jun 1;77(6):1141-1149 . doi: 10.1093/gerona/glac018.
  39. Raffin J, de Souto Barreto P, Le Traon AP, Vellas B, Aubertin-Leheudre M, Rolland Y. Sedentary behavior and the biological hallmarks of aging. Ageing Res Rev. 2022 Nov 22;83:101807. doi: 10.1016/j.arr.2022.101807. Epub ahead of print.
  40. Rouch L, Rolland Y, Hanon O, Vidal JS, Cestac P, Sallerin B, Andrieu S, Vellas B, Barreto PS; MAPT/DSA Group. Blood pressure, antihypertensive drugs, and incident frailty: The Multidomain Alzheimer Preventive Trial (MAPT). Maturitas. 2022 Aug;162:8-14. doi: 10.1016/j.maturitas.2022.03.001.
  41. Rouch L, Virecoulon Giudici K, Cantet C, Guyonnet S, Delrieu J, Legrand P, Catheline D, Andrieu S, Weiner M, de Souto Barreto P, Vellas B; Alzheimer's Disease Neuroimaging Initiative. Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the Alzheimer's disease neuroimaging initiative: cross-sectional and longitudinal retrospective analyses. Am J Clin Nutr. 2022 Oct 17:nqac236. doi: 10.1093/ajcn/nqac236. Epub ahead of print.
  42. Sánchez-Sánchez JL, Ader I, Jeanson Y, Planat-Benard V, Vellas B, Casteilla L, de Souto-Barreto P. Periostin plasma levels and changes on physical and cognitive capacities in community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2022 Nov 14:glac226. doi: 10.1093/gerona/glac226. Epub ahead of print.
  43. Sanchez-Sanchez JL, Giudici KV, Guyonnet S, Delrieu J, Li Y, Bateman RJ, Parini A, Vellas B, de Souto Barreto P; MAPT/DSA Group. Plasma MCP-1 and changes on cognitive function in community-dwelling older adults. Alzheimers Res Ther. 2022 Jan 7;14(1):5. doi: 10.1186/s13195-021-00940-2.
  44. Sanchez-Sanchez JL, He L, Virecoulon Giudici K, Guyonnet S, Parini A, Dray C, Valet P, Pereira O, Vellas B, Rolland Y, de Souto Barreto P. Circulating Levels of Apelin, GDF-15 and Sarcopenia: Lack of Association in the MAPT Study. J Nutr Health Aging. 2022;26(6):564-570. doi: 10.1007/s12603-022-1800-1.
  45. Schietzel S, Chocano-Bedoya PO, Sadlon A, Gagesch M, Willett WC, Orav EJ, Kressig RW, Vellas B, Rizzoli R, da Silva JAP, Blauth M, Kanis JA, Egli A, Bischoff-Ferrari HA. Prevalence of healthy aging among community dwelling adults age 70 and older from five European countries. BMC Geriatr. 2022 Mar 2;22(1):174. doi: 10.1186/s12877-022-02755-8.
  46. Stahl-Gugger A, de Godoi Rezende Costa Molino C, Wieczorek M, Chocano-Bedoya PO, Abderhalden LA, Schaer DJ, Spahn DR, Orav EJ, Vellas B, da Silva JAP, Kressig RW, Egli A, Bischoff-Ferrari HA; DO-HEALTH Research Group. Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial. Aging Clin Exp Res. 2022 Sep;34(9):2205-2215 . doi: 10.1007/s40520-022-02093-0.
  47. Tavassoli N, de Souto Barreto P, Berbon C, Mathieu C, de Kerimel J, Lafont C, Takeda C, Carrie I, Piau A, Jouffrey T, Andrieu S, Nourhashemi F, Beard JR, Soto Martin ME, Vellas B. Implementation of the WHO integrated care for older people (ICOPE) programme in clinical practice: a prospective study. Lancet Healthy Longev. 2022 Jun;3(6):e394-e404. doi: 10.1016/S2666-7568(22)00097-6.
  48. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2022 Nov 29. doi: 10.1056/NEJMoa2212948. Epub ahead of print.
  49. Wang HY, Trocmé-Thibierge C, Stucky A, Shah SM, Kvasic J, Khan A, Morain P, Guignot I, Bouguen E, Deschet K, Pueyo M, Mocaer E, Ousset PJ, Vellas B, Kiyasova V. Retraction Note: Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer's disease pathogenesis. Alzheimers Res Ther. 2022 Jun 1;14(1):76. doi: 10.1186/s13195-022-01024-5.
Bruno VELLAS Publications 2021 I Publications 2020 I Publications 2019